logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hiroyasu Kaneda

osaka metropolitan university
H指数:35
被引数:5,925

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC

TTF-1表达对PD-L1阴性NSCLC患者接受双重ICI与化疗联合免疫疗法预后分层的预测价值

International Journal of Clinical Oncology
IF2.8
2026-08-040
PRE
Naoya Nishioka; Daiki Murata; Koichi Azuma; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Takenori Sakai; Taishi Harada; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Tadaaki Yamada; Koichi Takayama
Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society

对胸癌患者提供医疗信息的定量评估：日本肺癌协会患者满意度调查

International Journal of Clinical Oncology
IF2.8
2026-05-270
PRE
Takayuki Takahama; Hidefumi Shimizu; Kenichi Yoshimura; Hidehito Horinouchi; Hiroyasu Kaneda; Kiyotaka Watanabe; Hiromi Aono; Keiko Tanaka; Seiki Hasegawa; Tomohiro Osawa; Hidetoshi Hayashi; Takeshi Yoshida; Yasuhisa Ohde; Tomoki Kimura; Mitsutoshi Akiho; Hatoe Sakamoto; Mayumi Ito; Kazuo Hasegawa; Koji Onishi; Jiichiro Sasaki; Satoshi Oizumi; Tetsuya Mitsudomi; Akihiko Gemma; Toshiyuki Sawa
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)

拉姆昔替尼联合厄洛替尼治疗EGFR突变非鳞非小细胞肺癌初治患者伴胸腔积液患者的II期研究（RELAY-Effusion）

Lung Cancer
IF4.4
2026-05-030
OAAI
Hiroyasu Kaneda; Motoko Tachihara; Yukihiro Toi; Shoichi Kuyama; Eiki Ichihara; Yasuhito Fujisaka; Koichi Azuma; Takayasu Kurata; Akihito Kubo; Hisashi Tanaka; Tadaaki Yamada; Toshihide Yokoyama; Takahide Kato; Ken Yamamoto; Nobuyuki Katakami; Ryota Kawai; Hisako Yoshida; Ayumi Shintani; Kenji Sawa; Tomoya Kawaguchi
Anti-Programmed Death-Ligand 1 Antibody-Associated Eosinophilic Granulomatosis with Polyangiitis in Non-Small Cell Lung Cancer: A Case Report

抗程序性死亡配体1抗体相关嗜酸性肉芽肿性多血管炎在非小细胞肺癌中的病例报告

Internal Medicine
IF1.1
2025-12-010
PRE
Sugimoto, Akira; Kaneda, Hiroyasu; Nozuchi, Satoshi; Mino, Toshikazu; Hasegawa, Itsuki; Mizutani, Megumi; Nagamine, Hiroaki; Matsumoto, Yoshiya; Oka, Takako; Tani, Yoko; Yamada, Kazuhiro; Watanabe, Tetsuya; Asai, Kazuhisa; Itoh, Yoshiaki; Kawaguchi, Tomoya
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病（合并与不合并CTLA-4方案）在PD-L1 < 1 %的非小细胞肺癌患者中的研究：一项多中心、回顾性研究

Lung Cancer
IF4.4
2025-09-260
PRE
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)

度伐利尤单抗联合伊立替康+顺铂用于未经治疗的广泛期小细胞肺癌：REBORN，II期研究（WJOG13520L）

Lung Cancer
IF4.4
2025-06-290
OA
Motoko Tachihara; Hiroyasu Shoda; Yuki Akazawa; Takayo Ota; Masahide Oki; Yuki Sato; Shunichi Sugawara; Satoshi Ikeda; Toshihide Yokoyama; Hiroyasu Kaneda; Shoichi Itoh; Akihiro Bessho; Nobuyuki Katakami; Satoshi Morita; Kazuhiko Nakagawa; Isamu Okamoto; Nobuyuki Yamamoto
A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)

伊立替康-顺铂联合度伐利尤单抗治疗初治广泛期小细胞肺癌的II期研究（WJOG13520L，REBORN试验）

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Tachihara, M.; Shoda, H.; Akazawa, Y.; Ota, T.; Oki, M.; Sato, Y.; Sugawara, S.; Ikeda, S.; Yokoyama, T.; Kaneda, H.; Itoh, S.; Bessho, A.; Katakami, N.; Morita, S.; Nakagawa, K.; Okamoto, I.; Yamamoto, N.
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
LANCET RESPIRATORY MEDICINE
IF32.8
2024-11-011
PRE
Shiraishi, Yoshimasa; Nomura, Shogo; Sugawara, Shunichi; Horinouchi, Hidehito; Yoneshima, Yasuto; Hayashi, Hidetoshi; Azuma, Koichi; Hara, Satoshi; Niho, Seiji; Morita, Ryo; Yamaguchi, Masafumi; Yokoyama, Toshihide; Yoh, Kiyotaka; Kurata, Takayasu; Okamoto, Hiroaki; Okamoto, Masaki; Kijima, Takashi; Kasahara, Kazuo; Fujiwara, Yutaka; Murakami, Shuji; Kanda, Shintaro; Akamatsu, Hiroaki; Takemoto, Shinnosuke; Kaneda, Hiroyasu; Kozuki, Toshiyuki; Ando, Masahiko; Sekino, Yuta; Fukuda, Haruhiko; Ohe, Yuichiro; Okamoto, Isamu
Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer
SCIENTIFIC REPORTS
IF3.9
2024-08-230
OAAI
Sugimoto, Akira; Kaneda, Hiroyasu; Yoshimoto, Naoki; Nagata, Kenji; Fujii, Tatsuo; Michimoto, Koichi; Ueno, Shunsuke; Kamimori, Takao; Ishii, Yoshie; Sakagami, Mai; Inokuchi, Haruo; Shibuya, Keiko; Mizutani, Megumi; Nagamine, Hiroaki; Nakahama, Kenji; Matsumoto, Yoshiya; Tani, Yoko; Sawa, Kenji; Kawaguchi, Tomoya

研究方向

暂未获取到该数据
K
Kazuhiko Nakagawa
H 指数:103论文数:1,451被引数:6.1万
K
Kazuto Nishio
H 指数:81论文数:1,116被引数:2.2万
K
Kazuko Sakai
H 指数:52论文数:614被引数:8,296
Y
Yoko Tani
H 指数:7论文数:71被引数:243
I
Isamu Okamoto
H 指数:75论文数:756被引数:3.2万
Y
Yoshiya Matsumoto
H 指数:10论文数:92被引数:327
T
Tokuzo Arao
H 指数:39论文数:243被引数:4,707
K
Kanae Kudo
H 指数:17论文数:94被引数:1,150
K
Keiichi Aomatsu
H 指数:16论文数:67被引数:1,098
Y
Yoshihiko Fujita
H 指数:55论文数:412被引数:9,788